Literature DB >> 18284364

Ischemic cardiac events during the Department of Health and Human Services Smallpox Vaccination Program, 2003.

David L Swerdlow1, Martha H Roper, Juliette Morgan, Richard A Schieber, Laurence S Sperling, Mercedes M Sniadack, Linda Neff, Jacqueline W Miller, Christine R Curtis, Mona E Marin, John Iskander, Pedro Moro, Paige Hightower, Nancy H Levine, Mary McCauley, James Heffelfinger, Inger Damon, Thomas J Török, Melinda Wharton, Eric E Mast, Gina T Mootrey.   

Abstract

Ten ischemic cardiac events (ICEs) were reported among 37,901 initial US Department of Health and Human Services (DHHS) smallpox vaccinees. Symptoms developed a median of 10 days after vaccination (range, 0-28 days). The median age of case patients was 56 years (range, 42-65 years), and 60% were male. Seven (70%) of the case patients had >/=3 cardiac risk factors or probable coronary artery disease before vaccination. Two women, 55 and 57 years of age, experienced acute myocardial infarction and fatal cardiac arrests. Background rates of ICEs during a 3-week period for civilian populations that were age and sex matched to DHHS vaccinees were estimated. The observed number of myocardial infarctions exceeded estimated expectations (5 vs. 2) but remained within the 95% predictive interval (PI) (0.6-5.4). New onset angina was observed significantly less frequently than estimated expectations (1 vs. 10; 95% PI, 3.5-15.7). After persons with >/=3 cardiac risk factors or known heart disease were deferred from vaccination, no ICEs were reported among an additional 6638 vaccinees.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18284364     DOI: 10.1086/524745

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

1.  Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System.

Authors:  Michael M McNeil; Maria Cano; Elaine R Miller; Brett W Petersen; Renata J M Engler; Marthe G Bryant-Genevier
Journal:  Vaccine       Date:  2014-06-18       Impact factor: 3.641

Review 2.  Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.

Authors:  Stephen R Walsh; Raphael Dolin
Journal:  Expert Rev Vaccines       Date:  2011-08       Impact factor: 5.217

Review 3.  ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.

Authors:  Aysegul Nalca; Elizabeth E Zumbrun
Journal:  Drug Des Devel Ther       Date:  2010-05-25       Impact factor: 4.162

4.  Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

Authors:  Stephen R Walsh; Marissa B Wilck; David J Dominguez; Elise Zablowsky; Shringkhala Bajimaya; Lisa S Gagne; Kelly A Verrill; Jane A Kleinjan; Alka Patel; Ying Zhang; Heather Hill; Aruna Acharyya; David C Fisher; Joseph H Antin; Michael S Seaman; Raphael Dolin; Lindsey R Baden
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

5.  Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox.

Authors:  Huiyong Wei; Dan Huang; Jeff Fortman; Richard Wang; Linyun Shao; Zheng W Chen
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.